世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

炎症性腸疾患治療薬市場:タイプ別(潰瘍性大腸炎、クローンズ病)、薬物クラス別(TNF阻害剤、コルチコステロイド、アミノサリチル、JAK阻害剤、抗インテグリン、IL阻害剤、その他)、流通チャネル別(病院薬局、ドラッグストアと小売薬局、オンラインショップ)。世界の機会分析および産業予測、2021-2031年


Inflammatory Bowel Disease Drugs Market By Type (Ulcerative Colitis, Crohns Disease), By Drug Class (TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, Others), By Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

世界の炎症性腸疾患治療薬市場は、2021年に209億8800万ドルで、2022年から2031年にかけてCAGR5.1%を記録し、2031年には345億1356万ドルに達すると予測されます。 炎症性腸疾患は、腸に慢性的な炎症を起こす疾患... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Allied Market Research
アライドマーケットリサーチ
2022年7月31日 US$5,820
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
274 英語

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

世界の炎症性腸疾患治療薬市場は、2021年に209億8800万ドルで、2022年から2031年にかけてCAGR5.1%を記録し、2031年には345億1356万ドルに達すると予測されます。
炎症性腸疾患は、腸に慢性的な炎症を起こす疾患群で、消化器疾患の一種である。潰瘍性大腸炎やクローン病などが含まれ、いずれも消化器系に影響を及ぼす疾患です。これらの病気は炎症が長引くと、消化管の障害につながります。潰瘍性大腸炎は、消化管内の大腸に炎症を起こし、消化器系以外の疾患を引き起こします。一方、クローン病は、消化管のあらゆる部位に炎症を起こし、主に小腸の末端部が侵されます。

炎症性腸疾患治療薬市場の成長を促す主な要因は、慢性炎症性腸疾患の憂慮すべき増加、医薬品産業発展のための政府の取り組みの増加、潰瘍性大腸炎治療薬の承認件数の増加などです。また、Marc D Bassonが行った潰瘍性大腸炎に関する調査によると、2019年には約100万人がUCに罹患しているとのことです。さらに、クローン病・大腸炎財団(CCFA)によると、2020年には米国で約7万人の炎症性腸疾患の症例が診断されており、潰瘍性大腸炎疾患の症例数の増加が市場の成長を牽引しています。さらに、欧州クローン病・潰瘍性大腸炎協会連合会(EFCCA)によると、2020年に炎症性腸疾患に罹患する人は世界で約1000万人、欧州で約340万人とされています。さらに、ECCFAはMedscape社と共同で、炎症性腸疾患の治療用バイオシミラーに関するトレーニングセッションを実施しています。このように、炎症性腸疾患の有病率の上昇や、疾患治療のための新しいソリューションを開発するための民間機関の連携などの要因が、市場の成長を促進しています。

また、Inflectra、Imraldi、Hyrimozなどのバイオシミラーの承認が増加し、効果的な治療法の採用が進むと予想されます。さらに、ファイザー株式会社が発売するIXFIやベーリンガーインゲルハイムのCyltezoといった他の薬剤の存在も、市場の成長を促進すると予想されます。例えば、2019年9月にヤンセン・バイオテック社が潰瘍性大腸炎の治療薬「STELARA(ウステキヌマブ)」のFDA承認を取得しました。STELARAは、インターロイキン12とインターロイキン23のサイトカインを標的とする潰瘍性大腸炎治療薬として初めて承認された薬剤です。インターロイキン12およびインターロイキン23は、炎症および免疫疾患反応において重要な役割を担っているサイトカインです。本剤は、新規の組織学的内視鏡的粘膜改善エンドポイントにより評価される腸管の改善効果をもたらします。また、2022年2月には、ジョンソン・エンド・ジョンソンが、現在乾癬の治療薬として承認されているTremfyaの安全性と有効性を紹介しましたが、今度はクローン病や潰瘍性大腸炎の治療薬として使用を開始することを後押ししています。このように、主要なプレーヤーによるクローン病や潰瘍性大腸炎の治療のための生物製剤やバイオシミラーの承認の増加は、市場の成長に向けて貢献しています。

欧米では、カナダで全人口の約0.6%が炎症性腸疾患の発症を経験していると報告されています。また、先進国では、炎症性腸疾患の有病率が急速に増加しています。また、近年、メタゲノム研究、生体情報解析技術が医学研究分野に登場し、炎症性腸疾患の治療研究に大きく寄与しています。このように、炎症性腸疾患の治療における新たなトレンドの高まりが、市場の成長を後押ししています。医学研究のインドジャーナルによると、2021年に、炎症性腸疾患の有病率は、衛生の欠如のために増加している。研究は、インドのVelloreから約200クローン病患者を示しています。したがって、個人の衛生に関する問題の増加は、市場の成長を推進しています。また、製薬業界の発展や医療費の改善は、炎症性腸疾患治療薬市場の成長を促進すると予想されています。現在、人々は順番に、彼らの健康状態を維持し、潰瘍性大腸炎薬の治療のための需要を高めるためにそれらを強制的に、健康のより多くの意識を持っています。これは、このように炎症性腸疾患薬市場における有利な成長機会を提供し、新興市場に参入する多くの主要プレーヤーを奨励している。

炎症性腸疾患の原因は、遺伝子、免疫系、環境要因の相互作用が関与していることが知られています。喫煙は、一貫して炎症性腸疾患と関連する因子である。例えば、2021年のIndian Journal of Medical Researchによると、アジア人における喫煙の有病率は65%でした。したがって、喫煙頻度の増加は、潰瘍性大腸炎のリスクを増加させ、炎症性腸疾患治療薬市場の成長に向けて貢献することが期待されます。しかし、特許切れや代替手術の可能性が市場の成長を制限しています。現在、人々は健康に対する意識が高く、その結果、彼らは自分の健康状態を維持し、潰瘍性大腸炎薬やクローン病薬の治療のための需要を高めることを余儀なくされている。 これは、このように炎症性腸疾患薬市場で有利な成長の機会を提供し、新興市場に参入する多くの主要な選手を奨励しています。

炎症性腸疾患治療薬市場は、タイプ、薬物クラス、および流通チャネルにわたって研究されています。タイプ別では、潰瘍性大腸炎とクローン病に区分されます。ドラッグクラスでは、TNF阻害剤、コルチコステロイド、アミノサリチル酸塩、JAK阻害剤、抗インテグリン剤、IL阻害剤、その他に細分化されています。流通チャネル別では、病院薬局、小売薬局、オンライン薬局に分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。
本レポートに記載されている主要企業は、AbbVie Inc.、Bristol Myers Squibb、Celltrion Healthcare、Eli-Lilly、Johnson & Johnson Services Inc、Merck & Co, Inc、Novartis AG、Pfizer Inc、Takeda Pharmaceutical Company Ltd、およびUCB S.A. です。

ステークホルダーにとっての主なメリット
本レポートは、2021年から2031年までの炎症性腸疾患治療薬市場分析における市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、炎症性腸疾患治療薬市場の優勢な機会を特定するものである。
●市場調査は、主要な推進要因、抑制要因、機会に関する情報とともに提供されます。
ポーターのファイブフォース分析により、買い手と供給者の潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、供給者と買い手のネットワークを強化できるようにします。
炎症性腸疾患治療薬の市場細分化に関する詳細な分析は、市場機会を決定するのに役立ちます。
炎症性腸疾患治療薬市場の詳細な分析は、市場機会を決定するのに役立ちます。
市場プレイヤーのポジショニングは、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
炎症性腸疾患治療薬の地域別および世界別の市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。

主な市場セグメント
タイプ別
潰瘍性大腸炎
クローンス病
薬物クラス別
TNF阻害剤
副腎皮質ホルモン剤
アミノサリチル酸塩
JAK阻害剤
抗インテグリン剤
IL阻害剤
その他
販売チャネル別
病院薬局
ドラッグストア・小売店
オンライン薬局

地域別
北米
アメリカ
カナダ
メキシコ
欧州
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
アジア太平洋地域
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
LAMEAの残りの地域

主な市場参加者
武田薬品工業株式会社
アッヴィー社
ファイザー
UCB S.A.
ジョンソン・エンド・ジョンソンサービス株式会社
ノバルティスAG
ブリストル・マイヤーズ スクイブ
エリー・リリー
メルク・アンド・カンパニーInc.
Celltrion Healthcare Co.

ページTOPに戻る


目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Ulcerative Colitis
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Crohns Disease
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.1.1 Market size and forecast
5.2 TNF inhibitors
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Corticosteroids
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Aminosalicylates
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 JAK inhibitors
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Anti-integrin
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 IL inhibitors
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Others
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
CHAPTER 6: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Store and Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Drug Class
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Drug Class
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Drug Class
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Drug Class
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Drug Class
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Drug Class
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Drug Class
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Drug Class
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Drug Class
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Drug Class
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Drug Class
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Drug Class
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Drug Class
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Drug Class
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Drug Class
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Drug Class
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Drug Class
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Drug Class
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Drug Class
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Drug Class
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Drug Class
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Drug Class
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Drug Class
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Takeda Pharmaceutical Company Limited
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AbbVie Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 UCB S.A.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson & Johnson Services, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Novartis AG
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Bristol Myers Squibb
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 ELI-LILLY
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Merck & Co. Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Celltrion Healthcare Co.,Ltd. 
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

 

ページTOPに戻る


 

Summary

The global inflammatory bowel disease drugs market was valued at $20,988 million in 2021 and is projected to reach $34.513.56 million by 2031 registering a CAGR of 5.1% from 2022 to 2031.
Inflammatory bowel disease is a group of disorders that causes chronic inflammation in the intestine and it is a type of gastrointestinal disease. It includes ulcerative colitis and Crohn’s disease, and both these types of diseases effect on digestive system. The prolonged inflammation of these diseases leads to damage of the gastrointestinal tract. The ulcerative colitis causes inflammation to the large intestine in the digestive tract and causes other non-digestive problems. Whereas, Crohn’s disease causes inflammation in any part of the digestive tract and it mainly affects the end part of the small intestine.

The main factors that foster the growth of the inflammatory bowel disease drugs market are alarming increase in number of chronic inflammatory bowel diseases, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for ulcerative colitis drugs. In addition, according to the survey conducted by Marc D Basson on Ulcerative Colitis, in 2019, about one million people were affected with UC. Moreover, as per Crohn’s and Colitis Foundation (CCFA), in 2020, around 70,000 cases of inflammatory bowel disease were diagnosed in the U.S. Thus, rise in number of cases of ulcerative colitis disease drives the growth of the market. Furthermore, according to the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA), there were around 10 million people suffering from inflammatory bowel disease in 2020 across the world and about 3.4 million in Europe. Furthermore, ECCFA has collaborated with Medscape to conduct training session on biosimilars for the treatment of inflammatory bowel disease. Thus, factors such as rise in prevalence of inflammatory bowel disease and collaboration among private institutions to develop new solutions for the treatment of the diseases propels the growth of the market.

In addition, increase in approval of biosimilars such as Inflectra, Imraldi, and Hyrimoz is expected to rise the adoption of effective treatment. In addition, the presence of other drugs such as IXFI which is launch by Pfizer Inc. and Cyltezo by Boehringer Ingelheim is expected to fuel the growth of the market. For instance, in September 2019, Janssen Biotech Inc. has received an FDA approval for its STELARA (ustekinumab) drug for the treatment of ulcerative colitis. STELARA is the first approved drug for ulcerative colitis which targets interleukin-12 and interleukin-23 cytokines. The interleukin-12 and interleukin-23 cytokines plays an important role in inflammatory and immune disease responses. It provides improvement of the intestinal tract as assessed by a novel histologic endoscopic mucosal improvement endpoint. In addition, in February 2022, Johnson & Johnson has introduced the safety and efficacy of Tremfya drug which is currently approved for the treatment of psoriasis but now it pushes to use for the treatment of Crohn’s and ulcerative colitis. Thus, increase in approval of biologics and biosimilars for the treatment of Crohn’s disease and ulcerative colitis by key players contribute towards the growth of the market.

In Western World, it was reported that there were increase in incidences of inflammatory bowel disease by about 0.6% out of the overall population in Canada. The prevalence of inflammatory bowel disease is increasing rapidly in developed countries. Moreover, in recent years the metagenomics research, bio-information analysis technology has begun to emerge in medical research field which contribute to inflammatory bowel disease treatment research greatly. Thus, rise in new trends in the treatment of inflammatory bowel disease drives the growth of the market. According to the Indian Journal of Medical Research, in 2021, the prevalence of inflammatory bowel disease has increasing due to lack of hygiene. The study shows that around 200 Crohn’s disease patients from Vellore, India. Thus, rise in issues regarding to personal hygiene drives the growth of the market. Moreover, development of pharmaceutical industries and improvement in healthcare spending are anticipated to drive the growth of the inflammatory bowel disease drugs market. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase the demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.

The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Smoking is a factor that is consistently associated with inflammatory bowel disease. For instance, according to Indian Journal of Medical Research in 2021, there were 65% prevalence of smoking in Asians. Thus, increase in frequency of smoking increases the risk of ulcerative colitis, which is expected to contribute toward the growth of the inflammatory bowel disease drugs market. However, patent expiry and availability of alternative surgery option for inflammatory bowel disease treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs and Crohn’s disease drugs .This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the inflammatory bowel disease drugs market.

The inflammatory bowel disease drugs market is studied across type, drug class, and distribution channel. On the basis of type, the market is segmented into ulcerative colitis, and Crohn’s disease. By drug class, the market is fragmented into TNF inhibitors, Corticosteroids, Aminosalicylates, JAK inhibitors, Anti-integrin, IL inhibitors, and others. By distribution channel, it is categorized into hospital pharmacy, retail pharmacy and online pharmacy. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
The key players mentioned in the report are AbbVie Inc., Bristol Myers Squibb, Celltrion Healthcare, Eli-Lilly, Johnson & Johnson Services Inc., Merck & Co, Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Ltd., and UCB S.A

Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the inflammatory bowel disease drugs market analysis from 2021 to 2031 to identify the prevailing inflammatory bowel disease drugs market opportunities.
●The market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
●In-depth analysis of the inflammatory bowel disease drugs market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global inflammatory bowel disease drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments
By Type
● Ulcerative Colitis
● Crohns Disease
By Drug Class
● TNF inhibitors
● Corticosteroids
● Aminosalicylates
● JAK inhibitors
● Anti-integrin
● IL inhibitors
● Others
By Distribution Channel
● Hospital Pharmacy
● Drug Store and Retail Pharmacy
● Online Pharmacy

By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ Australia
○ India
○ South Korea
○ Rest of Asia-Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA

● Key Market Players
○ Takeda Pharmaceutical Company Limited
○ AbbVie Inc.
○ Pfizer Inc.
○ UCB S.A.
○ Johnson & Johnson Services, Inc.
○ Novartis AG
○ Bristol Myers Squibb
○ ELI-LILLY
○ Merck & Co. Inc.
○ Celltrion Healthcare Co.,Ltd.



ページTOPに戻る


Table of Contents

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Ulcerative Colitis
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Crohns Disease
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DRUG CLASS
5.1 Overview
5.1.1 Market size and forecast
5.2 TNF inhibitors
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Corticosteroids
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Aminosalicylates
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 JAK inhibitors
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
5.6 Anti-integrin
5.6.1 Key market trends, growth factors and opportunities
5.6.2 Market size and forecast, by region
5.6.3 Market analysis by country
5.7 IL inhibitors
5.7.1 Key market trends, growth factors and opportunities
5.7.2 Market size and forecast, by region
5.7.3 Market analysis by country
5.8 Others
5.8.1 Key market trends, growth factors and opportunities
5.8.2 Market size and forecast, by region
5.8.3 Market analysis by country
CHAPTER 6: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospital Pharmacy
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Drug Store and Retail Pharmacy
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Online Pharmacy
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: INFLAMMATORY BOWEL DISEASE DRUGS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Type
7.2.3 North America Market size and forecast, by Drug Class
7.2.4 North America Market size and forecast, by Distribution Channel
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Type
7.2.5.1.2 Market size and forecast, by Drug Class
7.2.5.1.3 Market size and forecast, by Distribution Channel
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Type
7.2.5.2.2 Market size and forecast, by Drug Class
7.2.5.2.3 Market size and forecast, by Distribution Channel
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Type
7.2.5.3.2 Market size and forecast, by Drug Class
7.2.5.3.3 Market size and forecast, by Distribution Channel
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Type
7.3.3 Europe Market size and forecast, by Drug Class
7.3.4 Europe Market size and forecast, by Distribution Channel
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Type
7.3.5.1.2 Market size and forecast, by Drug Class
7.3.5.1.3 Market size and forecast, by Distribution Channel
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Type
7.3.5.2.2 Market size and forecast, by Drug Class
7.3.5.2.3 Market size and forecast, by Distribution Channel
7.3.5.3 UK
7.3.5.3.1 Market size and forecast, by Type
7.3.5.3.2 Market size and forecast, by Drug Class
7.3.5.3.3 Market size and forecast, by Distribution Channel
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Type
7.3.5.4.2 Market size and forecast, by Drug Class
7.3.5.4.3 Market size and forecast, by Distribution Channel
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Type
7.3.5.5.2 Market size and forecast, by Drug Class
7.3.5.5.3 Market size and forecast, by Distribution Channel
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Type
7.3.5.6.2 Market size and forecast, by Drug Class
7.3.5.6.3 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Type
7.4.3 Asia-Pacific Market size and forecast, by Drug Class
7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Type
7.4.5.1.2 Market size and forecast, by Drug Class
7.4.5.1.3 Market size and forecast, by Distribution Channel
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Type
7.4.5.2.2 Market size and forecast, by Drug Class
7.4.5.2.3 Market size and forecast, by Distribution Channel
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Type
7.4.5.3.2 Market size and forecast, by Drug Class
7.4.5.3.3 Market size and forecast, by Distribution Channel
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Type
7.4.5.4.2 Market size and forecast, by Drug Class
7.4.5.4.3 Market size and forecast, by Distribution Channel
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Type
7.4.5.5.2 Market size and forecast, by Drug Class
7.4.5.5.3 Market size and forecast, by Distribution Channel
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Type
7.4.5.6.2 Market size and forecast, by Drug Class
7.4.5.6.3 Market size and forecast, by Distribution Channel
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Type
7.5.3 LAMEA Market size and forecast, by Drug Class
7.5.4 LAMEA Market size and forecast, by Distribution Channel
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Type
7.5.5.1.2 Market size and forecast, by Drug Class
7.5.5.1.3 Market size and forecast, by Distribution Channel
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Type
7.5.5.2.2 Market size and forecast, by Drug Class
7.5.5.2.3 Market size and forecast, by Distribution Channel
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Type
7.5.5.3.2 Market size and forecast, by Drug Class
7.5.5.3.3 Market size and forecast, by Distribution Channel
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Type
7.5.5.4.2 Market size and forecast, by Drug Class
7.5.5.4.3 Market size and forecast, by Distribution Channel
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Takeda Pharmaceutical Company Limited
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AbbVie Inc.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 UCB S.A.
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Johnson & Johnson Services, Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Novartis AG
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Bristol Myers Squibb
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 ELI-LILLY
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Merck & Co. Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Celltrion Healthcare Co.,Ltd. 
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(通信回線)の最新刊レポート

Allied Market Research社の通信回線分野での最新刊レポート

本レポートと同じKEY WORD(colitis)の最新刊レポート


よくあるご質問


Allied Market Research社はどのような調査会社ですか?


アライドマーケットリサーチ(Allied Market Research)は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る